Discovery Labs (DSCO) +12.5% premarket after signing an agreement to manufacture and supply product for the commercial introduction of Afectair, a device that assists patients requiring ventilator support with the delivery of aerosolized medications. Afectair was cleared last week by the FDA for U.S. commercial use.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs